Merck Sharp & Dohme (MSD) refers to the Merck organization outside the U.S. and Canada and traces to the historic merger that combined Merck with Sharp & Dohme. It operates as a large pharmaceutical business under the Merck brand architecture.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
Secondary analysis of KEYNOTE-716 trial finds adjuvant pembrolizumab improves recurrence-free survival in stage IIB/IIC melanoma without increasing new primary melanoma risk, while reducing non-melanoma skin cancers.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07600775 |
A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07600749 |
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07600723 |
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037) |
NOT_YET_RECRUITING | PHASE4 |
| NCT07595263 |
A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07570173 |
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) |
RECRUITING | PHASE2/PHASE3 |
| NCT07557056 |
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07554339 |
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07548606 |
A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017) |
RECRUITING | PHASE1 |
| NCT07535359 |
Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer |
AVAILABLE | |
| NCT07532304 |
A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646) |
RECRUITING | PHASE1 |
